For patients with asymptomatic ICA stenosis and dyslipidemia unresponsive to conventional therapy with statins, whether or not associated with ezetimibe, the use of PCSK9 inhibitors should be considered (IIa/C).49-52. Here, PCSK9 is linked to metabolic syndrome.